The in vitro activity of the semisynthetic glycopeptide amide MDL 63,246 against 293 U.S. clinical isolates of gram-positive cocci was determined by the broth microdilution method. When compared with teicoplanin, MDL 63,246 had improved activity against Staphylococcus epidermidis (MICs that inhibited 90% strains tested [MIC 90 s], 0.25 versus 8 g/ml, respectively), Staphylococcus haemolyticus (MIC 90 s, 1 versus 32 g/ml, respectively), and VanA Enterococcus faecium (MIC 90 s, 32 versus >1,024 g/ml, respectively).
Mueller-Hinton II broth and horse blood were purchased from BBL and Remel (Lenexa, Kans.), respectively.
Broth microdilution susceptibility tests were performed by following a standardized protocol (11). All viridans group streptococci and S. pneumoniae isolates were tested in the presence of 2% lysed horse blood.
MICs for the S. aureus ATCC 29213 and E. faecalis ATCC 29212 control organisms consistently fell within the acceptable ranges of the National Committee for Clinical Laboratory Standards (11) for teicoplanin (0.25 to 1.0 and 0.06 to 0.25 g/ml, respectively) and vancomycin (0.5 to 2.0 and 1 to 4 g/ml, respectively). Table 1 summarizes the MDL 63,246, teicoplanin, mideplanin, and vancomycin MICs obtained for 293 recent U.S. clinical isolates of gram-positive cocci. The comparative in vitro activities of teicoplanin, mideplanin, and vancomycin mirror those reported previously (3, 4, 7, 8) . Briefly, teicoplanin is more active than vancomycin against the (non-VanA VanB) enterococci (MIC 90 s, 0.125 to 0.5 versus 1 to 2 g/ml, respectively), vancomycin is more active than teicoplanin against S. haemolyticus (MIC 90 s, 2 versus 32 g/ml, respectively), and mideplanin shows enhanced activity against the coagulase-negative staphylococci including S. haemolyticus. When compared with teicoplanin, MDL 63,246 has similar activity against S. aureus (MIC 90 s, of 0.25 versus 0.5 g/ml, respectively). However, compound MDL 63,246 (like mideplanin) shows increased activity against coagulase-negative staphylococci (including S. haemolyticus) and against VanA E. faecium (MIC 90 s Ն1,024 versus 32 g/ml, respectively). Like teicoplanin and mideplanin, MDL 63,246 has exquisite in vitro activity against the streptococci (MIC 90 s, Յ0.03 to 0.125 g/ml).
In summary, the present study demonstrates that the amide derivatives of the natural glycopeptide antibiotics teicoplanin and A40926 (MDL 62, 476) possess greater in vitro activity against coagulase-negative staphylococci and enterococci resistant to the parent compounds. This difference could be the result of enhanced bacterial cell wall penetration because of the increased basicity and lipophilicity of the compound (10) or to perturbation of VanS-VanR regulatory protein function. It has been shown that this two-component system regulates the synthesis of D-Ala-D-lactate peptidoglycan precursors in VanA E. faecium (2), and it has also been suggested that the difference in the regulation of glycopeptide resistance genes may account for the VanA and VanB phenotypes (1). A decrease in the affinity of the compound for the terminal D-Ala-D-lactate of the pentapeptide chains of VanA enterococcal peptidoglycan precursors appears highly unlikely, since VanB enterococci, which are highly susceptible to MDL 63,246, possess the same terminal depsipeptide (1). In contrast, intrinsically glycopeptide-resistant species of Leuconostoc, Pediococcus, and Lactobacillus have peptidoglycan precursors that terminate in D-Ala-D-Ala, and it has been suggested that the size of the side chains of the amino acids present in the pentapeptides of peptidoglycan precursors of these genera may affect glycopeptide binding (12). Further studies are needed to elucidate the mechanism for the increased activity of MDL 63,246 against VanA enterococci. Finally, an evaluation of the potential clinical utility of this antibiotic for the treatment of VanA enterococcal infections must await the outcome of pharmacokinetic studies. 
